Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H35F7N4O2.CH4O3S |
Molecular Weight | 712.719 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C2=C(C)C=C(F)C=C2)N3CCN(CC3)C(C)=O)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F
InChI
InChIKey=YRFKYVWDPCOSTE-REWBLLDVSA-N
InChI=1S/C30H35F7N4O2.CH4O3S/c1-18-13-24(31)5-6-26(18)27-17-25(40-11-9-39(10-12-40)20(3)42)7-8-41(27)28(43)38(4)19(2)21-14-22(29(32,33)34)16-23(15-21)30(35,36)37;1-5(2,3)4/h5-6,13-16,19,25,27H,7-12,17H2,1-4H3;1H3,(H,2,3,4)/t19-,25+,27-;/m1./s1
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C30H35F7N4O2 |
Molecular Weight | 616.6133 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19445564 |
http://adisinsight.springer.com/drugs/800018590
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19445564 |
http://adisinsight.springer.com/drugs/800018590
Casopitant (GW679769) is a novel substituted piperidine derivative that competitively binds with NK1 receptors. The full occupancy of the receptor by their piperidine compound
inhibits its binding with tachykinin neurotransmitters, including SP. Casopitant, in a series of in vitro and in vivo experimentations, has exhibited a potent NK1 receptor antagonism. On 29 May 2008, GlaxoSmithKline announced the submission of a new drug application to the FDA for intravenous and oral formulations of casopitant mesylate. This drug was proposed for the prevention of chemotherapy-induced nausea and vomiting as an add-on therapy to the standard dual therapy of 5-HT3 receptor antagonists + dexamethasone. The submission also included a proposed indication for postoperative nausea and vomiting prevention. Rezonic™ is the proposed trade name for casopitant mesylate in the United States; Zunrisa™ is the proposed trade name for casopitant mesylate for GlaxoSmithKline’s global group of companies. In September 2009, GlaxoSmithKline decided to discontinue all regulatory filings for casopitant based on an estimate of the amount of additional safety data.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL249 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24106886 |
10.2 null [pKi] | ||
Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21149541 |
9.86 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. | 2006 Apr 1 |
|
Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret. | 2008 Sep |
|
Disposition and metabolism of radiolabeled casopitant in humans. | 2009 Aug |
|
Antiemetic control: toward a new standard of care for emetogenic chemotherapy. | 2009 Mar |
|
Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. | 2009 Sep |
|
Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. | 2010 Aug |
|
Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. | 2010 Jul |
|
Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin. | 2010 May |
|
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. | 2010 Nov |
|
Management of chemotherapy-induced nausea and vomiting. | 2010 Sep-Oct |
|
A novel and integrated approach for the identification and characterization of drug-induced cardiac toxicity in the dog. | 2011 Feb |
|
Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists. | 2013 Dec |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19445564
A single 100 or 150 mg dose schedule of casopitant, orally or intravenously
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21149541
Casopitant inhibited CYP3A4 activity in human liver microsomes with an IC50 lower than 10 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:30:34 UTC 2023
by
admin
on
Fri Dec 15 16:30:34 UTC 2023
|
Record UNII |
7VSV9BL497
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID70194384
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY | |||
|
C531951
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY | |||
|
RR-52
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY | |||
|
414910-30-8
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY | |||
|
C61086
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY | |||
|
7VSV9BL497
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY | |||
|
100000092972
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY | |||
|
CHEMBL1672054
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY | |||
|
SUB28847
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY | |||
|
11686295
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY | |||
|
DBSALT002028
Created by
admin on Fri Dec 15 16:30:34 UTC 2023 , Edited by admin on Fri Dec 15 16:30:34 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |